US Food and Drug Administration has approved a device that has been shown to reduce seizures in patients with medication-resistant epilepsy by as much as 50 percent.
When the device is coupled with an innovative electrode placement planning system, it facilitates the complete elimination of seizures in nearly half of the implanted patients enrolled in the decade-long clinical trials, according to press release. Researchers believe its a breakthrough as nearly 400,000 people in the US living with epilepsy will be benefitted whose seizures cant be controlled with medications.
